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basis of these factors, they established an individual 
diagnostic index to define those groups of bacteremic 
patients who are at low or  high risk of I? aevuginosa 
bactereniia. Those associated factors (such as neutrophil 
defects, intensive care and cytotoxic or antibiotic treat- 
ment) identified by Gransden and coworkers have 
previously been recognized in several studies to render 
hospital patients particularly susceptible to I? aeuuginosa 
infection. In addition, the chances of identifying purely 
‘local’ factors that were not of general value was limited 
by the use of two different sets of patients from two 
different hospitals. The basic results of their study 
therefore appear to be well founded. 
Nevertheless, as was suggested by the authors 
themselves in the last paragraph of their report, the 
study did not provide useful information for the 
clinician, especially the intensivist, who is required 
daily to answer the following questions: Is the patient 
with a septic appearance truly bactereniic, and is this 
possibly bactereniic patient at  high risk of I? aeruginosa 
bacteremia? The design of the study and particularly 
the study population, which was limited to patients 
with bactereniia, do not help to answer these questions. 
Analysis of risk factors based on the comparison of 
patients with I! acvug’inosa bacteremia with those who 
have bactereniia due to other pathogens can only 
evaluate the likelihood with which l? aeruginosa was 
responsible after bacteriological diagnosis of bacteremia. 
Furthermore, the diagnostic index defined only those 
groups of bactereniic patients in whom I? aevuginosa was 
more likely to be causative than other pathogens. 
Is the use of such an index clinically relevant in 
patients known to be bacteremic (before determination 
of the staining and morphological characteristics of 
the bacteria isolated in the blood)? Are the initial 
therapeutic strategies different in the case of a 5.50/0, 
17.6% or 22.3% risk of bactereniia due to I? ueruginosa, 
as in the first validation set? Risk analysis remains the 
niajor epidemiological objective in different clinical 
settings, particularly acquisition of nosoconiial in- 
fection. Similarly, determination of groups of high-risk 
patients is one possible way to use prophylactic nieasures 
effectively. Such a determination, however, must be 
well founded and useful in clinical practice. 
Jean- Yves Fagon 
Paris, France 
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To the Editors: 
Terfenadine is a widely used non-sedating HI-selective 
antihistamine which has occasionally been associated 
with cardiac arrhythmias such as tovsades de  pointes, 
during overdosage [1] and in combination with other 
agents, such as ketoconazole [2,3] or some macrolide 
antibiotics [4]. The cardiac toxicity is the result of 
the direct quinidine-like action of terfenadine [5]. 
Recently, two reports have documented the occur- 
rence of cardiac arrhythmia during combined terfena- 
dine and itraconazole treatment [6,7]. To follow is a 
report of a case of malignant ventricular arrhythmia 
during treatment with this drug combination and a 
pharniacokinetic study of the two agents. 
An 18-year-old man was referred to our hospital 
in November 1993 with acute monocytic leukemia. 
Physical examination revealed no abnorniality except a 
raised body temperature. Serum electrolyte concen- 
trations were normal. Electrocardiography (ECG) on 
admission showed a corrected QT (QTc) interval of 
340 nis at  a heart rate of 78 beatsmin-’. Transthoracic 
echocardiography was normal. The patient received 
intravenous antineoplastic chemotherapy, including 
idarubicin (13 mg/day for 5 days), cytosine-arabinoside 
(330 nig/day for 7 days) and broad-spectrum antibiotics 
for the persistent fever. All investigations for an infec- 
tive agent were negative. The patient was then given 
prophylactic itraconazole (400 trig once daily; Janssen, 
Boulogne-Billancourt, France) as well as terferiadirie 
(60 nig twice daily; Marion Merrell I h w ,  Levallois- 
Perret, France) because of the pruriginous toxiderniia. 
All of the drugs were administered by a nurse. Ikspite 
broad-spectrum antibacterial therapy, the patient 
remained febrile and intravenous aniphotericin B 
(1 nig/kg/day) was prescribed. O n  the sixth day of 
itraconazole and terfenadine therapy, the patient 
experienced transient generalized seizures arid cardiac 
arrest. The ECG demonstrated ventricular fibrillation. 
The patient’s serum potassium concentration was 
3.4 niniol/L and serum magnesium concentration 
was 0.92 mmol/L. Liver and kidney functions were 
normal. Resuscitation procedures included the use of 
mechanical ventilation, application of four electric 
shocks and administration of niagnesium sulfate. 
Terfenadine and itraconazole were discontinued on the 
same day, after which no arrhythmia or seizure was 
observed. The QTc  interval remained prolonged for 3 
days after cardiac arrest and, after 15 days, the patient 
developed neurological symptoms related to anoxic 
encephalopathy and persistence of blast cells in the 
bone marrow. 
Blood samples were taken 10, 23, 32, 48, 56, 72  
and 96 h after the last dose of terfenadine and kept 
frozen until needed. Itraconazole and hydroxyitra- 
conazole were determined by liquid chromatography 
with fluorescence detection. In brief, a Hypersil 011s 
5 p 250 x 4 nini column was used, with a mobile phase 
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containing acetonitrile-water-triethylamine 550-450- 
2.8 v-v, adjusted to pH 2.3 by orthophosphoric acid. 
Itraconazole and hydroxyitraconazole were detected by 
excitation at 260 nm and fluorescence at 365 nm. The 
limits of quantification were 30 ng/mL for itraconazole 
and 17 ng/mL for hydroxyitraconazole; reproducibility 
was better than 6% over the calibration range of 50 to 
2000 ng/mL. 
Concentrations of terfenadine and its acid meta- 
bolite (Ml) were determined by high-pressure liquid 
chromatography (HPLC) [8]. The detection limit of 
the method was 1 ng.mL-' for both compounds. The 
serum concentration of unmetabolized terfenadine was 
high at 10 h and was still detectable up to 48 h after the 
last dose. Serum MI concentration was extremely high 
and remained so for up to 96 h. The elimination half- 
life of the metabolite was approximately 21 h (normal 
17 h). The results of the HPLC pharmacokinetic 
analysis of terfenadine, MI and itraconazole are given 
in Table 1. 
This case illustrates ventricular arrhythmia during 
treatment with itraconazole and terfenadine. An 
hypothesis of torsades de pointes complicated by 
ventricular fibrillation is likely, as indicated by the 
increased QTc interval. In this patient, administration 
of magnesium sulfate may explain the absence of 
recurrence. The arrhythmia was most probably due to 
the combination of itraconazole and terfenadine as 
torsades de pointes have been described during terfena- 
dine treatment combined with ketoconazole [2,3], but 
not with fluconazole 191. Cardiac arrhythmia has more 
recently been observed with terfenadine and itracona- 
zole [6,7]. In one report [6], the Q T c  interval was 
prolonged for 5 days and the unmetabolized terfena- 
dine level elevated for 13 days before arrhythmia. 
However, serum drug concentrations were not available 
for the day the arrhythmia occurred. In the other report 
[7], the QTc  interval was prolonged for 3 days and the 
unmetabolized terfenadine level remained elevated for 
up to 60 h after the last oral dose of terfenadine; serum 
itraconazole concentration was not measured. 
Usually, in patients taking therapeutic doses of 
terfenadine, unmetabolized terfenadine concentrations 
are very low or undetectable [8]. In our patient, the first 
serum sample - taken 10 h after the last terfenadine 
dose - showed a high concentration of unmetabolized 
drug (8.1 ng/mL vs normal < 1 ng/mL), which may 
explain the ventricular arrhythmia, as terfenadine is 
able to block the transient outward current in human 
atrial myocytes [lo]. 
Terfenadine normally undergoes first-pass meta- 
bolism in the liver to its active metabolite and leaves no 
detectable parent drug in the serum. This first-pass 
metabolism makes the drug vulnerable to interaction 
with other agents that are also acted upon by cyto- 
chrome P-450 3A4 and also susceptible to accumu- 
lation where these other agents have a higher affinity 
for the enzyme. The in-vitro metabolism of terfenadine 
has been reported to be sensitive to such interactions in 
experiments using human liver microsomes [ 1 I]. 
Ketoconazole has been shown to delay terfenadine 
metabolism, resulting in accumulation of unmetabol- 
ized parent drug and significant prolongation of 
the Q T c  interval [12,13] and, in a recent report of 
terfenadine given in association with itraconazole [ 141, 
there was accumulation of unmetabolized terfenadine 
and alteration of cardiac repolarization. 
In our patient, the QTc  interval normalized with 
the elimination of itraconazole. However, in healthy 
volunteers, there was a wide intersubject variability 
of ECG responses to terfenadine accumulation [I31 
and itraconazole-induced changes in terfenadine 
pharmacokinetics [14]. Therefore, cofactors such as 
electrolyte disorders may contribute to the develop- 
ment of ventricular arrhythmia. As our patient's serum 
potassium concentration was 3.4 mmol/L at the time 
of cardiac arrest, decreased intracellular potassiuni 
cannot be excluded as a possible cause. Ketoconazole 
alone was reported to prolong the QT interval in 
healthy volunteers [ 151 and to block potassium currents 
in feline heart [16]. To the best ofour knowledge, such 
effects have not been reported with itraconazole, but 
this agent is not known to have clinically significant 
effects on cardiac repolarization [14]. 
Table 1 High-pressure liquid chromatographic pharmaco- 
kinetic analysis of terfenadine, its acid metabolite (Ml) and 
itraconazole plus hydroxyitraconazole (Itr + OH-Itr) 
Time from last terfenadine administration (h) 
Agent (ng/mL) 10 23 32 48 56 72 96 
Terfenadine 8.1 3.6 2.0 2.1 1.0 <1 <1 
M1 1255 927 686 406 231 144 111 
Itr+OH-Itr 1312 1194 1370 1574 1175 949 502 
Our patient also had a high plasma level of the 
active acid metabolite of terfenadine (1255 ng/mL) 
compared with the usual peak serum level (250 
to 300 ng/mL) 3 h after steady-state dosing with 
terfenadine at 60 mg twice daily [8]. Such increased 
serum acid-metabolite levels have been observed 
during terfenadine overdosing 1171, terfenadine- 
ketoconazole interaction [2] and, more recently, in 
combination with itraconazole [7,14]. Honig and co- 
workers [I41 demonstrated that itraconazole inhibited 
the oxidative metabolization of MI to an inactive 
metabolite, M2. Increased concentrations of M1 have 
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no known deleterious effects on cardiac potassium 
channels [lo]. Genetic polymorphism in the meta- 
bolism of terfenadine niight explain elevated serum 
concentrations of both terfenadine and its active 
metabolite, although this seems unlikely. 
In conclusion, in the presence of itraconazole, 
circulating intact terfenadine levels remain high and are 
potentially responsible for severe arrhythmia. The role 
of an increased serum concentration of the acid 
metabolite requires further investigation. 
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In-vitro release of vancomycin and netilmicin from 
bone cement 
To the Editors: 
Despite all efforts, prosthetic infections still occur in 1 
to 2% of cases. Once established, infection can be 
difficult to treat with systeniic antibiotics. Several 
studies have shown that gram-positive bacteria, 
especially Staphylocoicus aiueus, coagulase-negative 
staphylococci, Enterococcus faecalis and Coryne- 
bacteriaceae, are responsible for 71 to 84%) of such 
infections Ill. 
In the management of infected joint implants, 
revision arthroplasty with the use of antibiotic-loaded 
acrylic cement (ALAC) has proven to be superior to 
other methods of currently available treatment 121. 
Furthermore, ALAC is a useful adjunct in the 
nianagenient of chronic osteomyelitis and in the 
prevention of recurrent osteoniyelitis after an initial 
attack [3].  Increasing antibiotic resistance of bacteria 
that infect prosthetic joints has stimulated interest in 
the incorporation of more effective antiniicrobial 
agents into acrylic cement. Vanconiycin is effective 
against all staphylococci, and aniinoglycosides have a 
wider spectrum of activity against gram-negative 
bacteria [4]. 
